BRIEF-Cytokinetics Announces FDA Approval Of Myqorzo™ (Aficamten)

Reuters12-20

BRIEF-<a href="https://laohu8.com/S/CYTK">Cytokinetics</a> Announces FDA Approval Of Myqorzo™ (Aficamten)

Dec 19 (Reuters) - Cytokinetics Inc CYTK.O:

CYTOKINETICS INC - MYQORZO EXPECTED TO BE AVAILABLE IN U.S. JANUARY 2026
CYTOKINETICS INC - MYQORZO INCLUDES BOXED WARNING FOR RISK OF HEART FAILURE
CYTOKINETICS ANNOUNCES FDA APPROVAL OF MYQORZO™ (AFICAMTEN) FOR THE TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
CYTOKINETICS INC - MYQORZO AVAILABLE ONLY THROUGH RESTRICTED REMS PROGRAM

Source text: ID:nGNX4L2G4W

Further company coverage: CYTK.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592197249?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-20 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592197249","market":"us","top_or_hot":-1,"title":"BRIEF-Cytokinetics Announces FDA Approval Of Myqorzo™ (Aficamten)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> Announces FDA Approval Of Myqorzo™ (Aficamten)</title></head><body><p><span>Dec 19 (Reuters)</span><span> - </span>Cytokinetics Inc <span>CYTK.O</span>:</p><ul><li><p>CYTOKINETICS INC - MYQORZO EXPECTED TO BE AVAILABLE IN U.S. JANUARY 2026</p></li><li><p>CYTOKINETICS INC - MYQORZO INCLUDES BOXED WARNING FOR RISK OF HEART FAILURE</p></li><li><p>CYTOKINETICS ANNOUNCES FDA APPROVAL OF MYQORZO™ (AFICAMTEN) FOR THE TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS</p></li><li><p>CYTOKINETICS INC - MYQORZO AVAILABLE ONLY THROUGH RESTRICTED REMS PROGRAM</p></li></ul><p>Source text: <span>ID:nGNX4L2G4W</span></p><p>Further company coverage: <span>CYTK.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cytokinetics Announces FDA Approval Of Myqorzo™ (Aficamten)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cytokinetics Announces FDA Approval Of Myqorzo™ (Aficamten)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-20 05:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> Announces FDA Approval Of Myqorzo™ (Aficamten)</title></head><body><p><span>Dec 19 (Reuters)</span><span> - </span>Cytokinetics Inc <span>CYTK.O</span>:</p><ul><li><p>CYTOKINETICS INC - MYQORZO EXPECTED TO BE AVAILABLE IN U.S. JANUARY 2026</p></li><li><p>CYTOKINETICS INC - MYQORZO INCLUDES BOXED WARNING FOR RISK OF HEART FAILURE</p></li><li><p>CYTOKINETICS ANNOUNCES FDA APPROVAL OF MYQORZO™ (AFICAMTEN) FOR THE TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS</p></li><li><p>CYTOKINETICS INC - MYQORZO AVAILABLE ONLY THROUGH RESTRICTED REMS PROGRAM</p></li></ul><p>Source text: <span>ID:nGNX4L2G4W</span></p><p>Further company coverage: <span>CYTK.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA9D7FCB:1","article_id":"2592197249","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592197249","pubTimestamp":1766178702,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cytokinetics Announces FDA Approval Of Myqorzo (Aficamten)Dec 19 (Reuters) - Cytokinetics Inc CYTK.O:CYTOKINETICS INC - MYQORZO EXPECTED TO BE AVAILABLE IN U.S. JANUARY 2026CYTOKINETICS INC - MY","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","CYTK":"Cytokinetics"},"translate_title":"简介-Cytokinetics宣布FDA批准Myqorzo™（Aficamten）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":0.9},"content_text":"BRIEF-Cytokinetics Announces FDA Approval Of Myqorzo™ (Aficamten)Dec 19 (Reuters) - Cytokinetics Inc CYTK.O:CYTOKINETICS INC - MYQORZO EXPECTED TO BE AVAILABLE IN U.S. JANUARY 2026CYTOKINETICS INC - MYQORZO INCLUDES BOXED WARNING FOR RISK OF HEART FAILURECYTOKINETICS ANNOUNCES FDA APPROVAL OF MYQORZO™ (AFICAMTEN) FOR THE TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMSCYTOKINETICS INC - MYQORZO AVAILABLE ONLY THROUGH RESTRICTED REMS PROGRAMSource text: ID:nGNX4L2G4WFurther company coverage: CYTK.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592197249","isCrawlerRequest":true}